![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS Number:4552N Celsis International PLC 07 February 2008 CELSIS INTERNATIONAL PLC ("Celsis", "the Company" or "the Group") INTERIM MANAGEMENT STATEMENT 7 February 2008: Celsis International plc, the life sciences products and laboratory services company, today provides its Interim Management Statement for the quarter ended 31 December 2007. Celsis has continued to see strong trading into the second half of the financial year following its positive interim results. Excellent performances have been seen from the Rapid Detection and In Vitro Technologies divisions, particularly during December, and the Group overall continues to trade in line with the Board's expectations. The Rapid Detection division, which provides rapid microbial detection systems to more quickly ensure product safety and quality, has continued to build on its solid first half instrument placements and reagent and consumable sales, with strong demand across all geographical regions and sectors of this business. This positive trend is expected to continue for the remainder of the financial year. The In Vitro Technologies division, which provides in vitro products and development services to the pharmaceutical and biotechnology industries to reduce the time and cost of drug discovery and development, remains on track and has seen very good trading during this quarter. Encouraging growth from this division is expected to continue as its sales team builds momentum and strengthens its presence in both North America and the EU. First full year results from the IVT division are expected to be healthy with a strong mix of product sales. The Analytical Services division, which provides outsourced laboratory testing services to the pharmaceutical industry, has seen good progress from three of its four business areas in this quarter, although there has been continued consolidation of the Celsis New Jersey chemistry business following excellent prior year performance. Focused marketing and business development plans are in place to recover this segment but are not likely to come to full fruition before the year end. Although the other three businesses are progressing well, the Analytical Services division is expected to complete the full year slightly down on last year's exceptional 25% increase. Commenting on today's announcement, Jay LeCoque, CEO of Celsis said: "Celsis is well positioned to grow organically, with progress in the Rapid Detection and In Vitro Technologies divisions being particularly encouraging during the quarter. In addition, we continue to review new acquisition opportunities. Overall, the Company looks forward to a positive year end performance, with revenue and profit growth in line with the Board's expectations." ENQUIRIES: Celsis International plc Tel: 01223 598 428 Jay LeCoque, Chief Executive Officer Christian Madrolle, Finance Director and Company Secretary Financial Dynamics Tel: 020 7831 3113 Ben Atwell David Yates Notes to editors Celsis International plc Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas; rapid detection, analytical and drug development services and ADME-Tox in vitro technologies. The company is listed on the London Stock Exchange (CEL.L) Each division of Celsis International plc has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical and biopharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing. Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical and biotechnology industries. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange END IMSUUUBUPUPRGQQ
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions